These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 9019754

  • 21. [Treatment of stage III non-small lung carcinomas: is there controversy?].
    Mornex F, Girard N.
    Rev Pneumol Clin; 2006 Dec; 62(6 Pt 2):2S20-3. PubMed ID: 17404534
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments.
    van Meerbeeck JP, Surmont VF.
    Lung Cancer; 2009 Sep; 65(3):257-67. PubMed ID: 19285751
    [Abstract] [Full Text] [Related]

  • 27. Current treatment recommendations for stage III non-small-cell lung carcinoma.
    Davis MP, Sause WT.
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):587-93. PubMed ID: 16258455
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Combined modality therapy of non-small cell lung cancer.
    Ruckdeschel JC.
    Semin Oncol; 1997 Aug; 24(4):429-39. PubMed ID: 9280223
    [Abstract] [Full Text] [Related]

  • 30. [On ''Multimodal treatment of clinical non-small cell N2 bronchogenic carcinoma: what is the answer?''].
    González Aragoneses F.
    Arch Bronconeumol; 2007 Mar; 43(3):183-4; author reply 184. PubMed ID: 17386198
    [No Abstract] [Full Text] [Related]

  • 31. [Therapy of bronchial carcinoma: interdisciplinary and with expertise].
    Thomas M.
    Pneumologie; 2002 Feb; 56(2):90-3. PubMed ID: 11842345
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer.
    Garland L, Robinson LA, Wagner H.
    Chest Surg Clin N Am; 2001 Feb; 11(1):69-100, viii. PubMed ID: 11253602
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Prognostic factors and therapeutic strategy in non-small-cell bronchial carcinoma].
    Wolf M.
    Praxis (Bern 1994); 1997 Oct 15; 86(42):1640-6. PubMed ID: 9432685
    [Abstract] [Full Text] [Related]

  • 39. [What is the value of neoadjuvant therapy in bronchial carcinoma?].
    Digel W, Brethner L, Hasse J.
    Zentralbl Chir; 2000 Oct 15; 125(4):315-8. PubMed ID: 10829310
    [Abstract] [Full Text] [Related]

  • 40. Combined modality therapy for stage III non-small cell lung cancer.
    Stinchcombe TE, Fried D, Morris DE, Socinski MA.
    Oncologist; 2006 Oct 15; 11(7):809-23. PubMed ID: 16880240
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.